Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by PharmaMar
Sponsor:
Information provided by (Responsible Party):
PharmaMar
ClinicalTrials.gov Identifier:
NCT01314599
First received: March 9, 2011
Last updated: April 21, 2014
Last verified: April 2014
  Purpose

Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183.


Condition Intervention Phase
Acute Leukemia
Drug: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.

Resource links provided by NLM:


Further study details as provided by PharmaMar:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) and Recommended Dose (RD) of PM01183 in patients with advanced acute leukemia. [ Time Frame: Up to 30 months ] [ Designated as safety issue: Yes ]
    The recommended dose (RD) will be the immediate lower DL below the MTD (maximum tolerated dose)with less than 1/3 of the first 6 evaluable patients experiencing DLT (dose limiting toxicity)during the induction, provided the RD is ≥ dose level 2. If the RD is determined at dose level 1, no further expansion will be done, and the study will be terminated.


Secondary Outcome Measures:
  • Antileukemic activity [ Time Frame: After induction/reinduction and every 4 weeks after treatment discontinuation; up to 30 months ] [ Designated as safety issue: No ]
    Activity will be defined according to the International Working Group (IWG) criteria.

  • Pharmacogenomic (PGx) profile of PM01183 in patients with advanced acute leukemia. [ Time Frame: Between day -24 to day 1 ] [ Designated as safety issue: No ]
    Identification of potential biomarkers of response to PM01183

  • Pharmacokinetics (PK) of PM01183 in patients with advanced acute leukemia [ Time Frame: Days 1 to 8 of induction and day 1 of next phase ] [ Designated as safety issue: No ]
    The PK will be elucidated using standard non-compartmental methods. The following parameters will be calculated: maximum drug concentration (Cmax), area under the curve (AUC), volume of distribution based on the terminal half-life (Vz), volume of distribution at steady state (Vss), clearance (CL) and half-life (t1/2)


Estimated Enrollment: 50
Study Start Date: May 2011
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
Drug: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion

PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.

Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183.


Detailed Description:

Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered as 1-hour intravenous (i.v.) infusion on three consecutive days (Days 1-3) to patients with advanced acute leukemia and to assess the safety profile and tolerability, to obtain preliminary information on the efficacy and to characterize the pharmacokinetics (PK) and pharmacogenomic (PGx) profile of PM01183.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Voluntarily signed and dated written informed consent
  • Age ≥ 18 years.
  • Patients must have a previous cytological or histological diagnosis of:

    • Relapsed or primary refractory non-M3 acute myeloid leukemia (AML) by the World Health Organization (WHO) criteria (irrespective of the number of prior regimens), either de novo or secondary [i.e., secondary to myelodysplastic syndromes (MDS), myeloproliferative neoplasms or previous chemotherapy for another condition].
    • Untreated AML in patients ≥ 65 years of age, if patients are not candidates for standard induction chemotherapy or have poor risk AML (i.e., secondary AML or AML with adverse cytogenetics or complex karyotype).
    • Accelerated or blastic phase chronic myeloid leukemia (CML, with progressive disease despite treatment with BCR-ABL kinase inhibitors), or chronic myelomonocytic leukemia (CMML).
    • Relapsed or refractory acute lymphoblastic leukemia (ALL) by WHO criteria.
  • Patients must have the following laboratory values prior to the start of treatment:

    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) range of values, unless due to elevated indirect bilirubin (e.g.,Gilbert's syndrome or hemolysis).
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
    • Alkaline phosphatase (AP) ≤ 2.5 x ULN.
    • Albumin ≥ 2.5 g/dl.
    • Calculated creatinine clearance (CrCl) ≥ 30 ml/min (using Cockcroft and Gault's formula).
    • Creatine phosphokinase (CPK) ≤ 2.5 x ULN.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • Negative pregnancy test for women of childbearing potential.

Exclusion Criteria:

  • Pregnant or lactating women; men and women of reproductive potential who are not using effective contraceptive methods throughout the treatment period and for six months after discontinuation of treatment.
  • Patients who plan to undergo allogeneic BM transplantation within four weeks.
  • Other relevant diseases or adverse clinical conditions:

    • History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.
    • Symptomatic or unstable cardiac arrhythmias, and/or prolonged QT-QTc grade ≥ 2.
    • History of significant neurological or psychiatric disorders that may affect the patient's compliance with the protocol assessments.
    • Active uncontrolled infection.
    • Myopathy or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 x ULN in two different determinations performed one week apart).
    • Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).
    • Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
  • Hematopoietic allogeneic stem cell transplantation within the last four months and/or active graft versus host disease, or prior autologous transplantation within the last four weeks.
  • Patients known to be human immunodeficiency virus (HIV) positive.
  • Cytotoxic chemotherapy within the last two weeks; radiation therapy within the last two weeks; biologic agents, including hematopoietic growth factors, within the last week; hydroxyurea, imatinib, corticosteroids and arsenic trioxide should be discontinued at least 24 hours prior to first study drug administration.
  • Treatment with any investigational product in the ≤ 5 half-lives period prior to inclusion in the study, or 30 days after therapy (in case of unknown half-life), unless evidence of rapid proliferating disease and upon discussion with the Sponsor.
  • Known hypersensitivity to any of the components of the drug product (DP).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01314599

Locations
United States, Minnesota
Mayo Clinic Terminated
Rochester, Minnesota, United States, 55905
United States, Texas
M.D. Anderson Cancer Center Recruiting
Houston,, Texas, United States, 77030
Contact: Guillermo García-Manero, M.D.       ggarciam@mdanderson.org   
Principal Investigator: Guillermo . García-Manero, M.D.         
Sponsors and Collaborators
PharmaMar
  More Information

No publications provided

Responsible Party: PharmaMar
ClinicalTrials.gov Identifier: NCT01314599     History of Changes
Other Study ID Numbers: PM1183-A-002-10
Study First Received: March 9, 2011
Last Updated: April 21, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by PharmaMar:
Leukemia
lurbinectedin
PM01183
Pharma Mar
Acute Leukemia in Relapse and Primary Refractory

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Leukemia
Acute Disease
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Neoplasms by Histologic Type
Disease Attributes
Pathologic Processes
Pharmaceutical Solutions
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014